All News

A new study says that more than 1 in 10 of the 17 million cancer survivors in the United States will die from cardiovascular disease (CVD).

The FDA Monday granted accelerated approval to voxelotor (Oxbryta) for the treatment of sickle cell disease in adults and pediatric patients 12 years or older.

With their ongoing study, the authors also hope to show the physical effect of exercise on function, quality of life, pain, and bone disease.

Over the next 5 years, mental health conditions are expected to become 1 of the most significant factors attributed to employer-sponsored healthcare benefit costs worldwide, according to survey findings.

Organizations should step up and improve rural health by offering new, innovative ways to improve access to the care that rural residents so desperately need.

Novartis AG announced their purchase agreement with cholesterol drugmaker Medicines Company; Trump is set to allow state importation of prescription drugs to curb rising drug prices; flu shot efficacy was found to be worse in people who are overwight, obese.

Predisposing risk factors include less than a high school education and hepatitis C coinfection.

Researchers may have identified a way to delay the progression of multiple sclerosis (MS) by blocking a molecule that controls the entry of B cells into the brain, which results in deterioration of tissue.

Without information about the possible severity of their condition, patients with psoriasis may not adhere to treatment, which could lead to worse outcomes.

Researchers in North Carolina reported discoveries that may lead to further understandings about how pancreatic cancer can become resistant to treatment.

This week, the top managed care news included research that shows stents may offer no more value than drugs for some heart patients; a ban on flavored tobacco products gains momentum; a survey finds most American families struggle with social factors that impact health.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

New Massachusetts legislation bans the sale of menthol products; a group of hospitals is suing HHS; the FDA has approved a new treatment for partial-onset seizures.

Quality of life and 6-minute walk test also improve with this treatment combination.

The link between prolonged opioid treatment and an increased frequency, severity of migraines has been attributed to the discovery of a peptide confirmed in mice that distinguishes the relationship of migraine pain and opioid-induced hyperalgesia (OIH), according to study findings.

For both in-network access and provider reimbursement rates, disparities between physical and behavioral healthcare is worsening for American families seeking affordable and available mental healthcare and addiction treatment, according to study findings.

BE READY is designed to evaluate the safety and efficacy of bimekizumab, humanized monoclonal IgG1 antibody that targets and neutralizes interleukin- (IL-)17A and IL-17F, a pair of cytokines that propel the inflammatory process through their effects on other messengers in the body that trigger chronic inflammatory response.

Regardless of the government's removal of cost and access obstacles to flu vaccinations, adherence remains stagnant; multistate hepatitis A outbreak linked to blackberries sold in grocery store chain; President Trump's FDA nominee Stephen Hahn avoids talk on the suspended e-cig flavor ban during his Senate confirmation hearing.

Humana outlined its progress in its third annual Value-Based Care Report, which details growth and evolution in this area since 2016, both in the number of agreements and in its spread across more parts of the country.

Researchers discovered new molecular drivers of Parkinson disease (PD) and determined their impact on the functions of genes involved in PD, potentially leading to novel treatments, according to study findings.

The FDA has approved a new treatment for adult patients with acute hepatic porphyria (AHP) a rare genetic disorder. Givlaari is an RNA interference therapeutic targeting aminolevulinic acid synthase 1. Simultaneously, Alnylam Pharmaceuticals announced a new framework for value-based agreements to help patients gain access to the treatment.

As part of its Quality Improvement Snapshots series, TMF Health Quality Institute issued 4 healthcare quality improvement efforts, highlighting the use of a rescue pack for patients with chronic obstructive pulmonary disease (COPD) as an impactful strategy in managing COPD-related exacerbations.

Chronic opioid therapy was found to disrupt sleep and increase the risk of sleep disorders, while prescription drug use for pain and sleep exhibited an increased risk of frailty among users, according to 2 study findings stressing the need for heightened prescription education among providers for potential adverse risks.

Under the ACA, patients with HIV in Medicaid expansion states have greater access to care.

A House committee approves a bill to ban all flavored tobacco products; anal cancer rates are on the rise; the debate continues over competing healthcare measures.

EMPRISE (Empagliflozin Comparative Effectiveness and Safety) will examine 5 years of real-world data on empagliflozin, which is sold as Jardiance by Eli Lilly and Boehringer Ingelheim. The study is comparing data on empagliflozin with that for dipeptidyl peptidase 4 (DPP-4) inhibitors. This latest interim analysis also features a cohort comparison with glucagon-like peptide 1 (GLP-1) receptor agonists.

Precision medicine may offer new hope to children with high-risk cancer, but only if families and healthcare professionals are fully educated on the benefits and limitations of precision medicine trials, according to a study in Journal of Clinical Oncology.

Tumor inflammatory response is significantly associated with poor prognosis in patients with multiple myeloma.